• Print

Emerging Companies

Attorneys on LeClairRyan’s Emerging Companies team have a depth of skill and experience representing emerging and high-growth companies in a full spectrum of industries. In the last decade, members of our team have represented hundreds of technology-based and high-growth businesses in fields such as biopharma, clean technology, communications, energy, finance, healthcare, information technology, insurance, internet, life sciences, manufacturing, media, medical devices and retail.

In every emerging company matter we handle, we strive to become our clients’ trusted advisor. In this role, we apply our knowledge, insight and skill to help our clients achieve their business objectives while managing and minimizing their legal risks, difficulties and expenses. 

LeClairRyan has represented emerging companies nationwide in financing transactions ranging from $25,000 to more than $50 million, and in mergers and acquisitions ranging from $10 million to more than $500 million. Our multidisciplinary team of attorneys understands the business nuances emerging companies face, and we regularly achieve favorable, quantifiable results for our clients.

Our distinctive strengths include:

  • Corporate formation and structure
  • Strategic and business counsel
  • Venture financing
  • Founder’s agreements
  • Employee incentives
  • Executive compensation
  • Boards of directors
  • Intellectual property protection
  • Product commercialization
  • Mergers and acquisitions
  • Immigration issues

Members of our team maintain strong business relationships with numerous venture capital firms, investment banks, accounting firms, universities, national laboratories, private equity funds and public companies. Through our involvement in these networks, we are strategically positioned to help our clients advance from one step to the next in the business lifecycle.

During the life cycle of an emerging company leading up to a liquidity event, our attorneys regularly serve as trusted advisors in connection with growth strategies, including strategic alliance arrangements such as joint ventures, co-marketing, co-development, licensing, distribution, teaming, contract manufacturing, and research and development agreements. In addition, in collaboration with other LeClairRyan attorneys, members of our team provide counsel on a full spectrum of legal issues that may arise during the lifespan of an emerging company, including litigation, tax, real estate, and wealth transfer issues.

Representative matters:

  • Represented emerging technology company in $19 million Series B financing
  • Represented executive team of venture-backed consumer electronics company in $590 million acquisition by Cisco, Inc.
  • Represented security technology company in $24 million acquisition by NASDAQ-listed technology company
  • Represented pharmaceutical research company in $45 million preferred stock offering
  • Represented financial planning technology developer in $17.5 million preferred stock offering
  • Represented commercial innovations company in $4.5 million convertible subordinated debenture offering
  • Represented venture-backed company specializing in development and production of magnetic bearings in the sale of substantially all its capital stock to strategic buyer. Transaction valued at $50 million with $10 million in potential earnout payments.
  • Represented topical eye drop compound developer in series of angel financing rounds amounting to more than $5 million in the aggregate
  • Represented phototherapy treatment developer in $3.5 million Series A financing
  • Represented provider of risk assessment and related management services in $1.5 million convertible debt financing
  • Represented manufacturer of water-in-fuel emulsification systems in $515,000 equity and convertible debt financing
  • Represented developer of cell therapy products in merger in which shareholders will receive $18 million in publically traded securities of NeoStem and royalty payments based on commercialization of its main product
  • Represented clinical-stage drug development company in $3 million private placement
  • Represented developer of soft tissue regeneration technology in $1.0 million Series A financing
  • Represented developer of recombinant human fibrogen and recombinant human factors IX and VII in $1.1 million two-stage investment and intellectual property licensing
  • Represented biomass-to-wood pellet conversion consultant in equity and debt financing up to $12 million in the aggregate
  • Represented hi-tech manufacturing company in collaborative technology license agreement with Siemens Energy, Inc. to advance state-of-the-art gas turbine performance
  • Represented adenosine-based pharmaceutical compound developer in closing of $350,000 seed round
  • Represented agricultural biotechnology company in closing of $300,000 seed round


  • 973.491.3358